Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants with relapsing multiple sclerosis (STRIVE-MS)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512319-40-00

Acronym

CCYB704A12301

Enrollment

Registered

2025-06-01

Start date

2025-07-01

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects with relapsing multiple sclerosis (relapsing remitting MS or active secondary progressive MS)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Bulgaria, Croatia, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026